Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
Joint Authors
Enteshary, A.
Moshkbar, M.
Salehzadeh, Farhad
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-01-09
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy.
Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high.
This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients.
American Psychological Association (APA)
Salehzadeh, Farhad& Enteshary, A.& Moshkbar, M.. 2019. Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients. Case Reports in Rheumatology،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1144197
Modern Language Association (MLA)
Salehzadeh, Farhad…[et al.]. Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients. Case Reports in Rheumatology No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1144197
American Medical Association (AMA)
Salehzadeh, Farhad& Enteshary, A.& Moshkbar, M.. Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients. Case Reports in Rheumatology. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1144197
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1144197
